BR112021015479A2 - Anticorpos anti-trem1 e métodos relacionados - Google Patents
Anticorpos anti-trem1 e métodos relacionadosInfo
- Publication number
- BR112021015479A2 BR112021015479A2 BR112021015479A BR112021015479A BR112021015479A2 BR 112021015479 A2 BR112021015479 A2 BR 112021015479A2 BR 112021015479 A BR112021015479 A BR 112021015479A BR 112021015479 A BR112021015479 A BR 112021015479A BR 112021015479 A2 BR112021015479 A2 BR 112021015479A2
- Authority
- BR
- Brazil
- Prior art keywords
- trem1
- related methods
- trem1 antibodies
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802161P | 2019-02-06 | 2019-02-06 | |
| US201962889994P | 2019-08-21 | 2019-08-21 | |
| PCT/US2020/016949 WO2020163564A2 (en) | 2019-02-06 | 2020-02-06 | Anti-trem1 antibodies and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021015479A2 true BR112021015479A2 (pt) | 2021-12-28 |
Family
ID=71947128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021015479A BR112021015479A2 (pt) | 2019-02-06 | 2020-02-06 | Anticorpos anti-trem1 e métodos relacionados |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20250179185A1 (https=) |
| EP (1) | EP3921344A4 (https=) |
| JP (2) | JP7492522B2 (https=) |
| KR (1) | KR20210126638A (https=) |
| CN (1) | CN113748132B (https=) |
| AU (1) | AU2020218525A1 (https=) |
| BR (1) | BR112021015479A2 (https=) |
| CA (1) | CA3128053A1 (https=) |
| CL (1) | CL2021002075A1 (https=) |
| CO (1) | CO2021010887A2 (https=) |
| CR (1) | CR20210462A (https=) |
| DO (1) | DOP2021000165A (https=) |
| IL (1) | IL284818A (https=) |
| MX (1) | MX2021009500A (https=) |
| PE (1) | PE20212269A1 (https=) |
| PH (1) | PH12021551903A1 (https=) |
| SG (1) | SG11202108570SA (https=) |
| TW (1) | TWI870382B (https=) |
| WO (1) | WO2020163564A2 (https=) |
| ZA (1) | ZA202210284B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260017009A (ko) | 2023-04-21 | 2026-02-04 | 셀시우스 테라퓨틱스, 인코포레이티드 | 항-trem1 항체 제제, 조성물 및 이의 용도 |
| WO2025201129A1 (zh) * | 2024-03-28 | 2025-10-02 | 北京丹序生物制药有限公司 | 一种抗触发受体-1抗体或其抗原结合片段及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150376294A1 (en) * | 2012-12-03 | 2015-12-31 | Rigshospitalet | Anti-pad2 antibodies and treatment of autoimmune diseases |
| JP6180663B2 (ja) * | 2014-12-23 | 2017-08-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｔｉｇｉｔに対する抗体 |
| DK3653221T5 (da) * | 2015-02-19 | 2024-08-26 | Compugen Ltd | Anti-pvrig-antistoffer og anvendelsesfremgangsmåder |
| WO2017127933A1 (en) * | 2016-01-29 | 2017-08-03 | The Governing Council Of The University Of Toronto | Frizzled protein-binding agents and methods of use thereof |
| WO2017152102A2 (en) * | 2016-03-04 | 2017-09-08 | Alector Llc | Anti-trem1 antibodies and methods of use thereof |
| KR20230119259A (ko) * | 2016-04-15 | 2023-08-16 | 이뮤넥스트, 인크. | 항-인간 vista 항체 및 이의 용도 |
-
2020
- 2020-02-06 KR KR1020217028210A patent/KR20210126638A/ko active Pending
- 2020-02-06 SG SG11202108570SA patent/SG11202108570SA/en unknown
- 2020-02-06 BR BR112021015479A patent/BR112021015479A2/pt unknown
- 2020-02-06 WO PCT/US2020/016949 patent/WO2020163564A2/en not_active Ceased
- 2020-02-06 EP EP20752176.6A patent/EP3921344A4/en active Pending
- 2020-02-06 CA CA3128053A patent/CA3128053A1/en active Pending
- 2020-02-06 CR CR20210462A patent/CR20210462A/es unknown
- 2020-02-06 CN CN202080027026.9A patent/CN113748132B/zh active Active
- 2020-02-06 PE PE2021001282A patent/PE20212269A1/es unknown
- 2020-02-06 JP JP2021545857A patent/JP7492522B2/ja active Active
- 2020-02-06 AU AU2020218525A patent/AU2020218525A1/en active Pending
- 2020-02-06 MX MX2021009500A patent/MX2021009500A/es unknown
- 2020-02-06 TW TW109103757A patent/TWI870382B/zh active
- 2020-02-06 PH PH1/2021/551903A patent/PH12021551903A1/en unknown
-
2021
- 2021-07-13 IL IL284818A patent/IL284818A/en unknown
- 2021-08-05 CL CL2021002075A patent/CL2021002075A1/es unknown
- 2021-08-06 DO DO2021000165A patent/DOP2021000165A/es unknown
- 2021-08-18 CO CONC2021/0010887A patent/CO2021010887A2/es unknown
-
2022
- 2022-09-16 ZA ZA2022/10284A patent/ZA202210284B/en unknown
-
2024
- 2024-05-17 JP JP2024080881A patent/JP7759996B2/ja active Active
- 2024-07-09 US US18/767,771 patent/US20250179185A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113748132A (zh) | 2021-12-03 |
| CL2021002075A1 (es) | 2022-04-01 |
| EP3921344A4 (en) | 2022-10-12 |
| JP2024105632A (ja) | 2024-08-06 |
| CO2021010887A2 (es) | 2021-09-09 |
| IL284818A (en) | 2021-08-31 |
| KR20210126638A (ko) | 2021-10-20 |
| CN113748132B (zh) | 2026-01-27 |
| PH12021551903A1 (en) | 2022-08-01 |
| SG11202108570SA (en) | 2021-09-29 |
| JP7492522B2 (ja) | 2024-05-29 |
| JP2022523145A (ja) | 2022-04-21 |
| AU2020218525A1 (en) | 2021-09-23 |
| DOP2021000165A (es) | 2021-09-30 |
| TW202037613A (zh) | 2020-10-16 |
| EP3921344A2 (en) | 2021-12-15 |
| WO2020163564A3 (en) | 2020-09-24 |
| PE20212269A1 (es) | 2021-11-30 |
| WO2020163564A2 (en) | 2020-08-13 |
| CR20210462A (es) | 2021-12-13 |
| TWI870382B (zh) | 2025-01-21 |
| MX2021009500A (es) | 2021-09-08 |
| US20250179185A1 (en) | 2025-06-05 |
| JP7759996B2 (ja) | 2025-10-24 |
| CA3128053A1 (en) | 2020-08-13 |
| ZA202210284B (en) | 2023-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550860A1 (en) | Anti-trem2 antibodies and related methods | |
| MX388410B (es) | Modulacion de celulas mieloides estimulantes y no estimulantes. | |
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| ZA202104246B (en) | Humanized anti-human-pd-1 antibody | |
| MX2024015440A (es) | Anticuerpos anti-phf-tau y usos de estos | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| AR111362A1 (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
| BR112023016574A2 (pt) | Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão | |
| BR112018071287A2 (pt) | composições compreendendo coformulação de anticorpos anti-pd-l1 e anti-ctla-4 | |
| BR112019007714A2 (pt) | anticorpos de 4-1bb anti-humanos e usos dos mesmos | |
| BR112018006531A2 (pt) | proteína isolada de ligação ao antígeno (abp), polinucleotídeo isolado, vetor, célula hospedeira, método para produzir uma proteína isolada de ligação ao antígeno (abp), composição farmacêutica, método para tratar ou prevenir uma doença ou condição num sujeito em necessidade deste, método para modular uma resposta imune num indivíduo em necessidade deste e kit | |
| EA201891435A1 (ru) | Гуманизированные моноклональные антитела, моноклональные антитела мыши или химерные моноклональные антитела против cd47 | |
| PH12018500663A1 (en) | Antigen-binding proteins that activate the leptin receptor | |
| PH12022550167A1 (en) | High concentration anti-c5 formulations | |
| EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| JOP20210297A1 (ar) | مواد وطرق لحث المناعة التي تساهم فيها الخلايا التائية | |
| MX2024010985A (es) | Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control. | |
| EA202092088A1 (ru) | Антитела анти-phf-тау и их применение | |
| BR112021015479A2 (pt) | Anticorpos anti-trem1 e métodos relacionados | |
| MX2022004058A (es) | Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo. | |
| EA202191929A1 (ru) | Днк-кодируемые моноклональные антитела, нацеленные на pd-1, для лечения и профилактики злокачественного заболевания | |
| EA202091458A1 (ru) | Анти-trem2 антитела и связанные с ними способы | |
| EA202192182A1 (ru) | Антитела к trem1 и соответствующие способы | |
| EA202090201A2 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |